

PRECEPTORSHIP PROGRAMME

Prostate Cancer

**ESMO
PRECEPTORSHIP**

**LUGANO SWITZERLAND
20-21 OCTOBER 2022**

Multidisciplinary management, standards of care, therapeutic targets and future perspectives.

Chairs:

Karim Fizazi, France

Silke Gillissen, Switzerland

ESMO PRECEPTORSHIP PROGRAMME PROSTATE CANCER

Multidisciplinary management, standards of care,
therapeutic targets and future perspectives

20-21 October 2022
Lugano, Switzerland

CO-CHAIRS: Karim Fizazi, France
Silke Gillesen, Switzerland

SPEAKERS: Daniel M. Berney, United Kingdom
Elena Castro, Spain
Daniela E. Oprea-Lager, Netherlands
Theo M. de Reijke, Netherlands
Thomas Zilli, Switzerland

LEARNING OBJECTIVES

- To learn about fundamentals of epidemiology, natural history and diagnosis as contributing factors to heterogeneity in prostate cancer
- To understand essentials in the assessment and multidisciplinary treatment of prostate cancer
- To learn about advances in treatment and novel targets in prostate cancer

ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Thursday, 20 October 2022

09:00-09:10 10'	Opening and welcome	
10'	Welcome from ESMO - Objectives and scientific introduction	Karim Fizazi, FR Silke Gillesen, CH
09:10-10:45 95'	SESSION 1 Screening, diagnosis, staging and localised prostate cancer	Chairs: Daniel M. Berney, UK Theo M. de Reijke, NL
15'	PSA screening and diagnosis	Theo M. de Reijke, NL
10'	Staging	Daniela E. Oprea-Lager, NL
15'	Pathological diagnosis for the clinician (including variants of PCa)	Daniel M. Berney, UK
15'	Treatment of localised prostate cancer according to risk category	Theo M. de Reijke, NL
15'	Radiotherapeutic approaches for localised prostate cancer	Thomas Zilli, CH
10'	Discussion	Faculty
15'	Participant's clinical case discussion	Participant
10:45-11:15	Coffee break	
11:15-12:35 80'	SESSION 2 Biochemical relapse	Chairs: Daniela E. Oprea-Lager, NL Thomas Zilli, CH
15'	Biochemical relapse: Definition and diagnostic algorithm	Daniela E. Oprea-Lager, NL
20'	Rising PSA after radical local treatment: Prognosis, indications for salvage local treatments, salvage vs adjuvant treatments	Thomas Zilli, CH
20'	Use of early vs deferred systemic treatments in high-risk localized CaP and biochemical failures	Karim Fizazi, FR
10'	Discussion	Faculty
15'	Participant's clinical case discussion	Participant
12:35-14:00	Lunch	
14:00-15:35 95'	SESSION 3 Systemic treatment options and molecular characterisation	Chairs: Elena Castro, ES Theo M. de Reijke, NL
20'	ADT and other hormonal treatments, mechanisms of action, main efficacy results and toxicities	Silke Gillesen, CH
20'	Chemotherapy (taxanes and platins) and Radium-223, mechanism of action, main efficacy results in Castration-Resistant Prostate Cancer (CRPC) and toxicities	Elena Castro, ES
15'	Bone health agents, mechanism of action, efficacy and toxicities	Karim Fizazi, FR
15'	Molecular characterisation: Germline and somatic testing	Elena Castro, ES
10'	Discussion	Faculty
15'	Participant's clinical case discussion	Participant

15:35-16:05	Coffee break	
16:05-17:30 85'	SESSION 4 Castration-sensitive metastatic prostate cancer	Chairs: Karim Fizazi, FR Silke Gillessen, CH
20'	Metastatic castration-sensitive prostate cancer (mCSPC)	Silke Gillessen, CH
15'	Triplet and quadruplet options (mCSPC)	Karim Fizazi, FR
10'	Monitoring of mCSPC	Daniela E. Oprea-Lager, NL
15'	Oligo-metastatic disease: What treatment?	Thomas Zilli, CH
10'	Discussion	Faculty
15'	Participant's clinical case discussion	Participant
19:00	Networking Dinner	

Friday, 21 October 2022

09:30-10:55 85'	SESSION 5 Non metastatic and metastatic castration-resistant disease	Chairs: Elena Castro, ES Daniela E. Oprea-Lager, NL
20'	Non metastatic CRPC: Current treatment	Karim Fizazi, FR
20'	Metastatic CRPC: Current treatment	Silke Gillessen, CH
20'	PSMA-based therapies	Daniela E. Oprea-Lager, NL
10'	Discussion	Faculty
15'	Participant's clinical case discussion	Participant
10:55-11:25	Coffee break	
11:25-12:25 60'	SESSION 6 Metastatic castration-resistant disease	Chairs: Karim Fizazi, FR Silke Gillessen, CH
15'	Treatment in frail patients with mCRPC	Elena Castro, ES
20'	Experimental treatments for mCRPC	Karim Fizazi, FR
10'	Discussion	Faculty
15'	Participant's clinical case discussion	Participant
12:25-12:35 10'	Conclusion and farewell	Karim Fizazi, FR Silke Gillessen, CH
12:35-13:35	Lunch	

Note: Each 15-minute slot for clinical case discussion includes a 7' case presentation and a 8' Q&A / panel discussion